ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
ImmunityBio shares surge on 700% revenue growth driven by sales of Anktiva, the company's approved drug for bladder cancer. Strong partnerships and clinical trials position Anktiva as key to its cancer treatment platform.